The US Food and Drug Administration (FDA) has announced significant measures to expedite the development of biosimilar medicines, aiming to reduce costs and increase accessibility.

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

The FDA’s new draft guidance aims to make the approval process faster and less burdensome by limiting the need for ...

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...